Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2018

01-06-2018 | Original Research

Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?

Authors: Mohammed Azeez Alzaidi, Hossein Ali Arab, Saeid Amanpour, Reza Shirkoohi, Samad Muhammadnejad, Farhang Sasani

Published in: Journal of Gastrointestinal Cancer | Issue 2/2018

Login to get access

Abstract

Purpose

Some epidemiological studies have shown an association between opium consumption and the incidence of gastrointestinal (GI) cancer. The present study was designed to investigate the effects of opium on the initiation of GI cancer in rats.

Methods

Forty-five rats were randomly divided into three groups; each received different treatment for 40 weeks. The rats in group 1 received purified water, while animals in group 2 were treated with 5 mg/kg diethylnitrosamine (DEN) orally for 8 weeks and continued with purified water by the end of the experiment. The third experimental group received 300 mg/kg opium for 16 weeks and then continued with 50 mg/kg phenobarbital by the end of the 40th week. The growth of tumors in the treated groups was assessed by histological changes and the up/down expression of p53, cdkn1, cdk2, e-cdh, and n-cdh genes in different parts of GI tract.

Results

Histological examinations revealed that DEN was able to induce the growth of tumor in GI tract as shown by active mitotic figure in different regions of GI system and hyperplasia of hepatocytes associated with infiltration of inflammatory cells, intestinal villous hypertrophy, and colorectal adenoma. There was also significant (p < 0.05) overexpression of p53, cdk2, and n-Cdh genes in different parts of digestive system in DEN-treated group. However, these pathological changes and the degradation of gene expression were not observed in the opium-treated group.

Conclusion

The results of this study suggest that the opium does not promote the initiation of cancer in GI tract.
Literature
1.
go back to reference Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359–63.PubMed Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359–63.PubMed
5.
go back to reference Aggrawal A. Opium: the king of narcotics. In: Aggrawal A, editor. Narcotic drugs. New Delhi: New Delhi National Book Trust; 1995. p. 161. Aggrawal A. Opium: the king of narcotics. In: Aggrawal A, editor. Narcotic drugs. New Delhi: New Delhi National Book Trust; 1995. p. 161.
6.
go back to reference United Nations Office on Drugs and Crime (UNODC). World drug report 2010. United Nations Publication Sales No.10.XI.13; 2010:1–50. United Nations Office on Drugs and Crime (UNODC). World drug report 2010. United Nations Publication Sales No.10.XI.13; 2010:1–50.
7.
go back to reference Heydari M, Hashem Hashempur M, Zargaran A. Medicinal aspects of opium as described in Avicenna’s Canon of Medicine. Acta Medico-Historica Adriatica. 2013;11(1):101–12.PubMed Heydari M, Hashem Hashempur M, Zargaran A. Medicinal aspects of opium as described in Avicenna’s Canon of Medicine. Acta Medico-Historica Adriatica. 2013;11(1):101–12.PubMed
11.
go back to reference Mousavi MRA, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003;113(11):1939–43.CrossRefPubMed Mousavi MRA, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003;113(11):1939–43.CrossRefPubMed
13.
go back to reference Hosseini SY, Safarinejad MR, Amini E, Hooshyar H. Opium consumption and risk of bladder cancer: a case-control analysis. In: Urologic Oncology: Seminars and Original Investigations. Elsevier; 2010. vol 6, p. 610–616. Hosseini SY, Safarinejad MR, Amini E, Hooshyar H. Opium consumption and risk of bladder cancer: a case-control analysis. In: Urologic Oncology: Seminars and Original Investigations. Elsevier; 2010. vol 6, p. 610–616.
15.
go back to reference Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells. Cancer Res. 2003;63(8):1846–52.PubMed Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells. Cancer Res. 2003;63(8):1846–52.PubMed
19.
go back to reference Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2008;67(8):3862–70.CrossRef Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2008;67(8):3862–70.CrossRef
21.
go back to reference Hayes AW, Kruger CL. Hayes’ principles and methods of toxicology. Boca Raton: CRC Press; 2014. Hayes AW, Kruger CL. Hayes’ principles and methods of toxicology. Boca Raton: CRC Press; 2014.
22.
go back to reference Lijinsky W. Chemistry and biology of N-nitroso compounds. Cambridge: Cambridge University Press; 1992. Lijinsky W. Chemistry and biology of N-nitroso compounds. Cambridge: Cambridge University Press; 1992.
24.
go back to reference Schmahl D. Combination effects in chemical carcinogenesis. In: Chambers PL, Klinger W, editors. Further studies in the assessment of toxic actions. Arch Toxicol Suppl. 1980;4:29–40. Schmahl D. Combination effects in chemical carcinogenesis. In: Chambers PL, Klinger W, editors. Further studies in the assessment of toxic actions. Arch Toxicol Suppl. 1980;4:29–40.
28.
go back to reference Pawan M, Choudhary R, Mathur R, Choudhary M, Kamla M. Study on harmful effects of opium on liver and lungs in chronic opium addicts of western Rajasthan. Journal of Bangladesh Society of Physiologist. 2011;6(2):122–6. Pawan M, Choudhary R, Mathur R, Choudhary M, Kamla M. Study on harmful effects of opium on liver and lungs in chronic opium addicts of western Rajasthan. Journal of Bangladesh Society of Physiologist. 2011;6(2):122–6.
33.
go back to reference El-Deiry W. P21/P53, cellular growth control and genomic integrity. Cyclin Dependent Kinase (CDK) Inhibitors. In: Current Topics in Microbiology and Immunology book series. 1998;227:121–137. El-Deiry W. P21/P53, cellular growth control and genomic integrity. Cyclin Dependent Kinase (CDK) Inhibitors. In: Current Topics in Microbiology and Immunology book series. 1998;227:121–137.
35.
go back to reference Zhu W, Abbas T, Dutta A. DNA Replication and Genomic. Genomic Advances in Experimental Medicine and Biology book series. 2005; 249–279. Zhu W, Abbas T, Dutta A. DNA Replication and Genomic. Genomic Advances in Experimental Medicine and Biology book series. 2005; 249–279.
Metadata
Title
Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?
Authors
Mohammed Azeez Alzaidi
Hossein Ali Arab
Saeid Amanpour
Reza Shirkoohi
Samad Muhammadnejad
Farhang Sasani
Publication date
01-06-2018
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2018
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-0050-7

Other articles of this Issue 2/2018

Journal of Gastrointestinal Cancer 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.